Here, we describe our treatment of a man age 39 years with multiply recurrent BRAF V600Ecraniopharyngioma using dabrafenib (150mg, orally twice daily) and trametinib (2mg, orally twice daily).
Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of CTNNB1 in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors).